CERo Therapeutics Partners with Colorado Center for AML Trial

CERo Therapeutics has launched its first clinical trial of CER-1236, a next-generation immunotherapy for acute myeloid leukemia (AML), at the Sarah Cannon Research Institute within the Colorado Blood Cancer Institute, a leading center in the region. This marks the first human trial for CER-1236, focusing on patients with relapsed or treatment-resistant AML, including those with TP53 mutations, with the aim of assessing safety, effectiveness, and optimal dosing. The trial uses innovative chimeric engulfment receptor technology, which researchers hope will improve remission rates and reduce relapse. Analysts at Boral Capital have initiated coverage of CERo Therapeutics with a Buy rating and an $11 price target, citing the company's unique T cell engineering platform and potential pipeline catalysts expected in 2025. Despite current low share prices and profitability challenges, experts suggest CERo is undervalued given its promising technology for both blood cancers and solid tumors. The company's strong cash position and leadership in immunology further support its positive outlook among long-term biotech investors.